Company hopes for MRSA drug

Independent
Neutec Pharma, an offshoot from the University of Manchester which is trialling a treatment for the hospital superbug, is to raise up to £25m to set up a sales force for its new products. The AIM-listed company launched the fund raising yesterday, after the publication of promising data on its other advanced drug, Mycograb, for the treatment of life-threatening fungal infections.